Identification of a novel mechanism of NF-κB inactivation by progesterone through progesterone receptors in Hec50co poorly differentiated endometrial cancer cells: Induction of A20 and ABIN-2

Gynecologic Oncology

Volumn 94, Issue 2, 2004, Pages 463-470

  Davies, Suzy ^a   Dai, Donghai ^a   Feldman, Irv ^b   Pickett, Gavin ^c   Leslie, Kimberly K ^a,d  

^a UNIVERSITY OF NEW MEXICO   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^d Repro Molecular Biology Laboratory   (United States)

Author keywords

A20; ABIN 2; Endometrial cancer; NF B; Progesterone receptors A and B

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROGESTERONE RECEPTOR;

ARTICLE; CANCER CELL; CELL DIFFERENTIATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA BINDING; DNA MICROARRAY; ENDOMETRIUM CARCINOMA; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; GENE INACTIVATION; GENETIC TRANSCRIPTION; GENOMICS; HUMAN; HUMAN CELL; INFLAMMATION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; CARRIER PROTEINS; CELL LINE, TUMOR; ELECTROPHORESIS; ENDOMETRIAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; NF-KAPPA B; NUCLEAR PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGESTERONE; PROTEIN BIOSYNTHESIS; PROTEINS; RECEPTORS, PROGESTERONE; RESPONSE ELEMENTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSFECTION;

EID: 3543050040     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2004.05.028     Document Type: Article

References (36)

1. Persson I., Adami H.O., Bergkvist L., et al. Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: results of a prospective study. BMJ. 298:1989;147-151
2. Antunes C.M., Strolley P.D., Rosenshein N.B., et al. Endometrial cancer and estrogen use. Report of a large case-control study. N. Engl. J. Med. 300:1979;9-13
3. Satyaswaroop P.G. Development of a preclinical model for hormonal therapy of human endometrial carcinomas. Ann. Med. 25:1993;105-111
4. Kreitmann B., Bugat R., Bayard F. Estrogen and progestin regulation of the progesterone receptor concentration in human endometrium. J. Clin. Endocrinol. Metab. 49:1979;926-929
5. Mote P.A., Balleine R.L., McGowan E.M., Clarke C.L. Colocalization of progesterone receptors A and B by dual immunofluorescent histochemistry in human endometrium during the menstrual cycle. J. Clin. Endocrinol. Metab. 84:1999;2963-2971
6. Mote P.A., Balleine R.L., McGowan E.M., Clarke C.L. Heterogeneity of progesterone receptors A and B expression in human endometrial glands and stroma. Hum. Reprod. 15(Suppl. 3):2000;48-56
7. Lange C.A., Shen T., Horwitz K.B. Phosphorylation of human progesterone receptors at serine-294 by mitogen-activated protein kinase signals their degradation by the 26S proteasome. Proc. Natl. Acad. Sci. U. S. A. 97:2000;1032-1037
8. Creasman W.T. Prognostic significance of hormone receptors in endometrial cancer. Cancer. 71:1993;1467-1470
9. Lin A., Karin M. NF-[kappa]B in cancer: a marked target. Semin. Cancer Biol. 13:2003;107-114
10. Ashburner B.P., Westerheide S.D., Baldwin A.S. Jr. The p65 (RelA) subunit of NF-kappaB interacts with the histone deacetylase (HDAC) corepressors HDAC1 and HDAC2 to negatively regulate gene expression. Mol. Cell. Biol. 21:2001;7065-7077
11. Madrid L.V., Mayo M.W., Reuther J.Y., Baldwin A.S. Jr. Akt stimulates the transactivation potential of the RelA/p65 Subunit of NF-kappa B through utilization of the Ikappa B kinase and activation of the mitogen-activated protein kinase p38. J. Biol. Chem. 276:2001;18934-18940
12. Baldwin A.S. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J. Clin. Invest. 107:2001;241-246
13. Baldwin A.S. Jr. Series introduction: the transcription factor NF-kappaB and human disease. J. Clin. Invest. 07:2001;3-6
14. Van Huffel S., Delaei F., Heyninck K., De Valck D., Beyaert R. Identification of a novel A20-binding inhibitor of nuclear factor-kappa B activation termed ABIN-2. J. Biol. Chem. 276:2001;30216-30223
15. Klinkenberg M., Van Huffel S., Heyninck K., Beyaert R. Functional redundancy of the zinc fingers of A20 for inhibition of NF-kappaB activation and protein-protein interactions. FEBS Lett. 498:2001;93-97
16. Vaskivuo T.E., Stenback F., Tapanainen J.S. Apoptosis and apoptosis-related factors Bcl-2, Bax, tumor necrosis factor-alpha, and NF-kappaB in human endometrial hyperplasia and carcinoma. Cancer. 95:2002;1463-1471
17. Seppanen M., Henttinen T., Lin L., et al. Inhibitory effects of cytokines on ovarian and endometrial carcinoma cells in vitro with special reference to induction of specific transcriptional regulators. Oncol. Res. 10:1998;575-589
18. Szekeres-Bartho J., Varga P., Kinsky R., Chaouat G. Progesterone-mediated immunosuppression and the maintenance of pregnancy. Res. Immunol. 141:1990;175-181
19. Yoshino O., Osuga Y., Hirota Y., et al. Endometrial stromal cells undergoing decidualization down-regulate their properties to produce proinflammatory cytokines in response to interleukin-1 beta via reduced p38 mitogen-activated protein kinase phosphorylation. J. Clin. Endocrinol. Metab. 88:2003;2236-2241
20. Dai D., Litman E.S., Schonteich E., Leslie K.K. Progesterone regulation of activating protein-1 transcriptional activity: a possible mechanism of progesterone inhibition of endometrial cancer cell growth. J. Steroid Biochem. Mol. Biol. 87:2003;123-131
21. Dai D., Wolf D.M., Litman E.S., White M.J., Leslie K.K. Progesterone inhibits human endometrial cancer cell growth and invasiveness: down-regulation of cellular adhesion molecules through progesterone B receptors. Cancer Res. 62:2002;881-886
22. Hermoso M.A., Cidlowski J.A. Putting the brake on inflammatory responses: the role of glucocorticoids. IUBMB Life. 55:2003;497-504
23. Dai D., Kumar N.S., Wolf D.M., Leslie K.K. Molecular tools to reestablish progestin control of endometrial cancer cell proliferation. Am. J. Obstet. Gynecol. 184:2001;790-797
24. Dixit V.M., Green S., Sarma V., et al. Tumor necrosis factor-alpha induction of novel gene products in human endothelial cells including a macrophage-specific chemotaxin. J. Biol. Chem. 265:1990;2973-2978
25. Leslie K.K., Tasset D.M., Horwitz K.B. Functional analysis of a mutant estrogen receptor isolated from T47Dco breast cancer cells. Am. J. Obstet. Gynecol. 166:1992;1053-1061
26. Smid-Koopman E., Blok L.J., Kuhne L.C., et al. Distinct functional differences of human progesterone receptors A and B on gene expression and growth regulation in two endometrial carcinoma cell lines. J. Soc. Gynecol. Investig. 10:2003;49-57
27. Hanekamp E.E., Gielen S.C., Smid-Koopman E. Consequences of loss of progesterone receptor expression in development of invasive endometrial cancer. Clin. Cancer Res. 9:2003;4190-4199
28. Coussens L.M., Werb Z. Inflammation and cancer. Nature. 420:2002;860-867
29. Orlowski R.Z., Baldwin A.S. Jr. NF-kappaB as a therapeutic target in cancer. Trends Mol. Med. 8:2002;385-389
30. Idel S., Dansky H.M., Breslow J.L. A20, a regulator of NF{kappa}B, maps to an atherosclerosis locus and differs between parental sensitive C57BL/6J and resistant FVB/N strains. Proc. Natl. Acad. Sci. 100:2003;14235-14240
31. Heyninck K., Beyaert R. Crosstalk between NF-kappaB-activating and apoptosis-inducing proteins of the TNF-receptor complex. Mol. Cell. Biol. Res. Commun. 4:2001;259-265
32. MacFarlane M. TRAIL-induced signalling and apoptosis. Toxicol. Lett. 139:2003;89-97
33. Guiochon-Mantel A., Lescop P., Christin-Maitre S., Loosfelt H., Perrot-Applanat M., Milgrom E. Nucleocytoplasmic shuttling of the progesterone receptor. EMBO J. 10:1991;3851-3859
34. King W.J., Greene G.L. Monoclonal antibodies localize oestrogen receptor in the nuclei of target cells. Nature. 307:1984;745-747
35. Perrot-Applanat M., Logeat F., Groyer-Picard M.T., Milgrom E. Immunocytochemical study of mammalian progesterone receptor using monoclonal antibodies. Endocrinology. 116:1985;1473-1484
36. Cusack J.C. Rationale for the treatment of solid tumors with the proteasome inhibitor bortezomib. Cancer Treat. Rev. 29:2003;21-31